The 10th World Congress on Controversies in Multiple Myeloma (COMy)
Hybrid Event
May 23 - 26, 2024
Paris, Ile-de-France, FR
15 CME 
OVERVIEW
The 10th World Congress on Controversies in Multiple Myeloma (COMy) is organized by CME Congresses Ltd and will be held from May 23 - 26, 2024 at Hotel Pullman Paris Montparnasse, Paris, Ile-de-France, France.
Description:
Over the last few years, the field of multiple myeloma has made significant progress. We have seen fascinating novel drugs being introduced and the whole treatment paradigm is progressively changing.
As in our previous congresses, this international meeting aims to deliver state-of-the-art science and research, focusing on the latest advances in the field and on improving patient care.
The scientific content will be cutting edge as the pace of change in multiple myeloma is accelerating.
Main Topics:
- Advances in disease biology
- AL amyloidosis
- CAR T cells in myeloma
- Choice of therapy for non-transplant eligible patients
- Guidelines in specific clinical situations
- Immunotherapy
- Minimal residual disease
- Ongoing clinical trials and future trials
- Options for refractory myeloma
- Outcome prediction
- Practical guidelines for the practicing physician
- Smoldering myeloma and MGUS
- Special session for patients’ advocacy group
- Treatment guidelines for young patients
- Treatment of relapse
- Waldenstrom macroglobulinemia
| Day 1, Thursday, May 23rd | |
|---|---|
| 08:30-10:00 | BCMA-targeted therapies in myeloma: the new treatment frontier Pre-COMy CME Symposium |
| 10:00-10:20 | Coffee Break |
| 10:20-10:30 | COMy 2023 kick-off: Welcome by the Congress Co-Chairs |
| 10:30-12:00 | Session 1: Defining risk in myeloma |
| Moderators: Joan Bladé, Spain; TBA | |
| 10:30-10:45 | MGUS risk stratification: Shaji Kumar, USA |
| 10:45-11:00 | Smoldering myeloma risk stratification: Irene Ghobrial, USA |
| 11:00-11:15 | Ultra high-risk disease in IMS consensus: Jill Corre, France |
| 11:15-11:30 | Genomic landscape of high-risk disease: Eileen Boyle, USA |
| 11:30-11:45 | Single cell analysis findings in high-risk disease: Marc Raab, Germany |
| 11:45-12:00 | Roundtable discussion: should we design risk-based protocols? All session faculty and Hervé Avet-Loiseau, France & Vincent Rajkumar, USA |
| 12:00-12:30 | Lunch Break |
| 12:30-14:00 | Industry-supported Lunch Symposium |
| 14:00-14:10 | Technical Break |
| 14:10-15:35 | Session 2: Novel approaches for disease and response assessment |
| Moderators: Roberto Mina, Italy; Kwee Yong, UK | |
| 14:10-14:25 | Optimizing MRD assessment: Bruno Paiva, Spain |
| 14:25-14:40 | Mass spectrometry: Noemi Puig, Spain |
| 14:40-14:55 | Immune monitoring in the context of immunotherapy: Niels van de Donk, Netherlands |
| 14:55-15:10 | Advances in imaging techniques: Elena Zamagni, Italy |
| 15:10-15:25 | The microbiota signature: Florent Malard, France |
| 15:25-15:35 | Roundtable discussion: should we design risk-based protocols? All session faculty and Gordon Cook, UK & Jesús San Miguel, Spain |
| 15:35-15:45 | Technical Break |
| 15:45-17:15 | Industry-supported Symposium |
| 17:15-17:30 | Coffee Break |
| 17:30-18:30 | Session 3: Precursor conditions and other plasma cell disorders |
| Moderators: Michel Delforge, Belgium; Murielle Roussel, France | |
| 17:30-17:45 | Screening for MGUS: hype or reality? Sigurdur Kristinsson, Iceland |
| 17:45-18:00 | Diagnosis and management of amyloidosis: Giampaolo Merlini, Italy |
| 18:00-18:15 | Diagnosis and management of Waldenström macroglobulinemia: Steven Treon, USA |
| 18:15-18:30 | Roundtable discussion: should we treat precursor conditions? All session faculty and Bertrand Arnulf, France & Fredrik Schjesvold, Norway |
| 18:30-19:15 | Session 4: Plenary lectures |
| Moderators: Holger Auner, Switzerland; Charlotte Pawlyn, UK | |
| 18:30-18:50 | Genomics of myeloma: the latest advances: Nikhil Munshi, USA |
| 18:50-19:15 | New mechanisms of disease resistance to T cell-based therapies: Paola Neri, Canada |
| Day 2, Friday, May 24th | |
|---|---|
| 07:00-07:30 | Good Morning Breakfast |
| 07:30-08:15 | Breakfast Session |
| 08:15-08:25 | Technical Break |
| 08:25-09:25 | Session 5: IMS Session |
| Moderators: Philippe Moreau, France; Nikhil Munshi, USA | |
| 09:25-09:35 | Technical Break |
| 09:35-11:05 | Industry-supported Morning Symposium |
| 11:05-11:20 | Coffee Break |
| 11:20-12:30 | Session 6: Frontline management of newly diagnosed myeloma |
| Moderators: Mario Boccadoro, Italy; TBA | |
| 11:20-11:35 | The optimal induction prior to transplant: Francesca Gay, Italy |
| 11:35-11:50 | The role of double transplant: Hartmut Goldschmidt, Germany |
| 11:50-12:05 | The evolving landscape of maintenance therapy: Laura Rosiñol, Spain |
| 12:05-12:20 | The optimal approach in very old and frail patients: Thierry Facon, France |
| 12:20-12:30 | Roundtable discussion: should we continue to transplant myeloma? All session faculty and Michele Cavo, Italy & Katja Weisel, Germany |
| 12:30-13:00 | Lunch Break |
| 13:00-14:30 | Industry-supported Lunch Symposium |
| 14:30-14:45 | Technical Break |
| 14:45-15:45 | Session 7: Practical management of specific situations |
| Moderators: Meral Beksac, Turkey; Lalit Kumar, India | |
| 14:45-15:00 | Extra-medullary disease: Philippe Moreau, France |
| 15:00-15:15 | Therapy of patients under dialysis: Aurore Perrot, France |
| 15:15-15:30 | Bone disease: the latest guidelines: Evangelos Terpos, Greece |
| 15:30-15:45 | Vaccinations and infectious prophylaxis: Heinz Ludwig, Germany |
| 15:45-16:00 | Coffee Break |
| 16:00-17:30 | Industry-supported Symposium |
| 17:30-17:45 | Technical Break |
| 17:45-18:45 | Session 8: Plenary lectures |
| Moderators: Suzanne Lentzsch, USA; Saad Usmani, USA | |
| 17:45-18:00 | CAR-T cells: present and future: Hermann Einsele, Germany |
| 18:00-18:15 | Bispecific antibodies: present and future: Nizar Bahlis, Canada |
| 18:15-18:30 | Minimizing toxicities after immunotherapy: Salomon Manier, France |
| 18:30-18:45 | Roundtable discussion: how to sequence immunotherapies? All session faculty and Ajai Chari, USA & Thomas Martin, USA |
| 18:45-19:15 | Award Ceremony: Presented by the Congress Co-Chairs |
| Day 3, Saturday, May 25th | |
|---|---|
| 06:30-07:00 | Good Morning Breakfast |
| 07:00-08:00 | CME Symposium |
| 08:00-08:10 | Technical Break |
| 08:10-09:10 | Session 9: Novel agents under development |
| Moderators: Michael O’Dwyer, Ireland; Rakesh Popat, UK | |
| 08:10-08:25 | CELMODs: Sagar Lonial, USA |
| 08:25-08:40 | Antibody-drug conjugates: Fredrik Schjesvold, Norway |
| 08:40-08:55 | Peptide conjugates: Enric Ocio, Spain |
| 08:55-09:10 | How to bridge patients prior to CAR-T cells? Paul Richardson, USA |
| 09:10-09:20 | Technical Break |
| 09:20-10:50 | Industry-supported Morning Symposium |
| 10:50-11:10 | Coffee Break |
| 11:10-12:25 | Session 10: How I treat a relapsed/refractory myeloma |
| Moderators: Bhagirathbhai Dholaria, USA; Joseph Mikhael, USA | |
| 11:10-11:25 | Clinical case presentation + Treatment options (1st relapse after transplant): Cyrille Touzeau, France |
| 11:25-11:40 | Clinical case presentation + Treatment options (1st relapse after anti-CD38+Rd): Alessandra Larocca, Italy |
| 11:40-11:55 | Clinical case presentation + Treatment options (triple class refractory young patient): Xavier Leleu, France |
| 11:55-12:10 | Clinical case presentation + Treatment options (triple class refractory elderly patient): Hira Mian, Canada |
| 12:10-12:30 | Roundtable discussion All session faculty and Claudio Cerchione, Italy & Joshua Richter, USA |
| 12:30-13:00 | Lunch Break |
| 13:00-14:30 | Industry-supported Lunch Symposium |
| 14:30-14:40 | Technical Break |
| 14:40-15:25 | Debate: Management of triple-class refractory patients in the absence of immunotherapies |
| 15:25-16:40 | Session 11: The road to cure: future protocols and directions |
| Moderators: Vincent Rajkumar, USA; TBA | |
| 15:25-15:40 | Young and fit patients: Pieter Sonneveld, Netherlands |
| 15:40-15:55 | Elderly and/or frail patients: Sonja Zweegman, Netherlands |
| 15:55-16:10 | Protocols for low- and middle-income countries: Vania Hungria, Brazil |
| 16:10-16:25 | How to design the best protocol? Jean-Luc Harousseau, France |
| 16:25-16:40 | Patients’ perspective and advocacy: Brian Durie, USA |
| 16:40-16:55 | Coffee Break |
| 16:55-17:55 | CME Symposium |
| 17:55-18:05 | Technical Break |
| 18:05-18:35 | Session 12: Plenary lecture |
| Moderators: Congress Co-Chairs | |
| 18:05-18:35 | Curing myeloma: from the bench to the bedside: Kenneth Anderson, USA |
| 18:35-18:45 | In-Person Conclusions: Summary by the Congress Co-Chairs |
| Day 4, Sunday, May 26th | |
|---|---|
| 09:00-10:30 | Session 13: Abstract communications I |
| 10:30-12:00 | Session 14: Abstract communications II |
| 12:00-12:30 | Final Panel Discussion and Conclusion |
KEY DATES
23 May, 2024
Event Start Date
26 May, 2024
Event End Date
ACCREDITATION & CREDITS
CME Accreditation:
The EBAH-CME Unit has approved this educational activity for a maximum number of CME credits. Each physician should only claim credits for time that she/he actually spent in the educational activity. We are pleased to inform you that the 2024 COMy Congress has been awarded.
- 15 (Fifteen) EBAH-CME Credit Points
All participants may print a European Board for Accreditation in Hematology (EBAH) CME certificate indicating the number of EBAH-CME Credit Points awarded, directly from the system on the CME section of the EBAH website at (www.ebah.org).
TARGET AUDIENCE
HematologistMedical OncologistsSPECIALITIES
HaematologyOncologySUGGESTED HOTELS
CONFERENCE VENUE
Hotel Pullman Paris MontparnasseCANCELLATION & REFUND POLICY
"Until April 9, 2024, a full refund will be issued (excluding a 50 Euro handling fee and any applicable bank charges). Refunds initiated after April 10, 2024, will be for 50% of the total. Cancellations sent after May 1, 2024, are not eligible for a refund."
REVIEWS (1)
well-organized!
RELATED CONFERENCES & LIVE WEBINARS
Quick Links